311 related articles for article (PubMed ID: 33057635)
1. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.
Vadakekolathu J; Lai C; Reeder S; Church SE; Hood T; Lourdusamy A; Rettig MP; Aldoss I; Advani AS; Godwin J; Wieduwilt MJ; Arellano M; Muth J; Yau TO; Ravandi F; Sweet K; Altmann H; Foulds GA; Stölzel F; Middeke JM; Ciciarello M; Curti A; Valk PJM; Löwenberg B; Gojo I; Bornhäuser M; DiPersio JF; Davidson-Moncada JK; Rutella S
Blood Adv; 2020 Oct; 4(20):5011-5024. PubMed ID: 33057635
[TBL] [Abstract][Full Text] [Related]
2. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
3. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Uy GL; Aldoss I; Foster MC; Sayre PH; Wieduwilt MJ; Advani AS; Godwin JE; Arellano ML; Sweet KL; Emadi A; Ravandi F; Erba HP; Byrne M; Michaelis L; Topp MS; Vey N; Ciceri F; Carrabba MG; Paolini S; Huls GA; Jongen-Lavrencic M; Wermke M; Chevallier P; Gyan E; Récher C; Stiff PJ; Pettit KM; Löwenberg B; Church SE; Anderson E; Vadakekolathu J; Santaguida M; Rettig MP; Muth J; Curtis T; Fehr E; Guo K; Zhao J; Bakkacha O; Jacobs K; Tran K; Kaminker P; Kostova M; Bonvini E; Walter RB; Davidson-Moncada JK; Rutella S; DiPersio JF
Blood; 2021 Feb; 137(6):751-762. PubMed ID: 32929488
[TBL] [Abstract][Full Text] [Related]
4. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Rimando JC; Chendamarai E; Rettig MP; Jayasinghe R; Christopher MJ; Ritchey JK; Christ S; Kim MY; Bonvini E; DiPersio JF
Blood; 2023 Apr; 141(14):1718-1723. PubMed ID: 36563336
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia.
Barwe SP; Kisielewski A; Bonvini E; Muth J; Davidson-Moncada J; Kolb EA; Gopalakrishnapillai A
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268423
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
Bi X; French Z; Palmisiano N; Wen KY; Wilde L
Ann Hematol; 2022 Jun; 101(6):1251-1259. PubMed ID: 35288759
[TBL] [Abstract][Full Text] [Related]
9. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
10. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
[TBL] [Abstract][Full Text] [Related]
13. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Vadakekolathu J; Minden MD; Hood T; Church SE; Reeder S; Altmann H; Sullivan AH; Viboch EJ; Patel T; Ibrahimova N; Warren SE; Arruda A; Liang Y; Smith TH; Foulds GA; Bailey MD; Gowen-MacDonald J; Muth J; Schmitz M; Cesano A; Pockley AG; Valk PJM; Löwenberg B; Bornhäuser M; Tasian SK; Rettig MP; Davidson-Moncada JK; DiPersio JF; Rutella S
Sci Transl Med; 2020 Jun; 12(546):. PubMed ID: 32493790
[TBL] [Abstract][Full Text] [Related]
14. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
Guy DG; Uy GL
Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of TP53-mutated myeloid malignancies.
Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
[TBL] [Abstract][Full Text] [Related]
16. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
17. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
19. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
20. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
